Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...

Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

Variant Bio today announced a partnership with Novo Nordisk for disease research and development that could total $50 million for the biotech startup. The Seattle company is working with genetically… ...

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...

Novo Nordisk partners with Variant Bio, paying up to $50M upfront for metabolic disease targets. Some funds will support Indigenous communities that provided data.

Speaking with Stat ahead of his exit, Robert Califf expressed concern about the potential for brain drain in government. Other news is on promising drugs for lung cancer patients, the upcoming J.P.

A case study published by researchers at Johns Hopkins University showed that optical genome mapping (OGM) detected a structural variant that was ...